Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000821 · ClinicalTrials.gov registry record · Phase 1

Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
78
Enrollment target
1
Study location

NCT00000821: Completed Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00000821 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 78 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000821, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

To compare the effects of low-dose versus high-dose subcutaneous ( SC ) aldesleukin ( interleukin-2; IL-2 ) on immunologic and virologic markers in HIV-infected patients. To compare the effects of monthly versus bimonthly administration of SC IL-2 on these markers. Interleukin-2 is a protein that is naturally produced by lymphocytes. In an initial study, patients in an earlier stage of HIV-1 infection tended to tolerate SC IL-2 better than those with more advanced infections, and those with higher baseline CD4+ counts tended to derive the greatest benefit.

Conditions Studied

HIV Infections

Interventions

  • DRUG Aldesleukin

Study Locations (1)

Maryland

  • Natl Inst of Allergy & Infect Dis / Cln Ctr - Bethesda

Trial Details

FieldValue
Enrollment Target 78 participants
Est. Completion 2002-03
Phase Phase 1
National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

What the finished NCT00000821 record still lists

NCT00000821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (83% lower).

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Aldesleukin is the first listed.

NCT00000821 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00000821 about?

NCT00000821 is a clinical study titled "Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients". To compare the effects of low-dose versus high-dose subcutaneous ( SC ) aldesleukin ( interleukin-2; IL-2 ) on immunologic and virologic markers in HIV-infected patients. To compare the effects of monthly versus bimonthly administration of SC IL-2 on these markers. Interleukin-2 is a protein that i...

What is the current status of trial NCT00000821?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. Estimated completion is 2002-03.

What conditions does trial NCT00000821 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000821?

The interventions under investigation include: Aldesleukin (DRUG).

Who is sponsoring clinical trial NCT00000821?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000821 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00000821's enrollment target sits among peer trials

78 302nd of 542 higher than 241 of 542 other HIV Infections trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02397668 · 78 participants · NA

    CorMatrix Cor TRICUSPID ECM Valve Replacement Study

  • NCT03321656 · 78 participants · Phase 2

    Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile

  • NCT03687814 · 78 participants · NA

    Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation

  • NCT04018872 · 78 participants · Phase 2

    Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

Related registry views

Source: ClinicalTrials.gov NCT00000821, the US trial registry maintained by the National Library of Medicine. NCT00000821 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.